Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sohyun Hwang

Showing results (81-90 of 84) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 84 results.
Clinical and Molecular Hepatology|December 28, 2025
Molecular determinants of outcome to gemcitabine, cisplatin, and nab-paclitaxel in patients with advanced biliary tract cancerDaeseong Kim, Nam Suk Sim, Seonjeong Woo, et al.
Clinical and Molecular Hepatology|October 28, 2025
Integrative Multi-Omics Profiling Identifies Infiltrative HCC as an Immunotherapy-Resistant Subtype with Distinct Molecular FeaturesWon Suk Lee, Seonjeong Woo, Sung Hwan Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2025
Bevacizumab plus erlotinib in advanced solid cancers with Krebs cycle gene mutations: A multicenter phase II study (BRISK; KCSG AL22-16)Hyehyun Jeong, Changhoon Yoo, Shinkyo Yoon, et al.
Journal of Hepatology|June 15, 2026
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinomaPasquale Lombardi, Erik Ramon-Gil, Rabial Q Raja, et al.
Pageof 9

Showing results (81-90 of 84) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 84 results.
Clinical and Molecular Hepatology|December 28, 2025
Molecular determinants of outcome to gemcitabine, cisplatin, and nab-paclitaxel in patients with advanced biliary tract cancerDaeseong Kim, Nam Suk Sim, Seonjeong Woo, et al.
Clinical and Molecular Hepatology|October 28, 2025
Integrative Multi-Omics Profiling Identifies Infiltrative HCC as an Immunotherapy-Resistant Subtype with Distinct Molecular FeaturesWon Suk Lee, Seonjeong Woo, Sung Hwan Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2025
Bevacizumab plus erlotinib in advanced solid cancers with Krebs cycle gene mutations: A multicenter phase II study (BRISK; KCSG AL22-16)Hyehyun Jeong, Changhoon Yoo, Shinkyo Yoon, et al.
Journal of Hepatology|June 15, 2026
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinomaPasquale Lombardi, Erik Ramon-Gil, Rabial Q Raja, et al.
Pageof 9